Entrada Therapeutics Inc Cash Flow Reinvestment Rate
Entrada Therapeutics Inc cash flow reinvestment rate. Entrada Therapeutics Inc (TRDA) has a Cash Flow Reinvestment Rate of 0.64x as of June 2024, reinvesting $25.43 Million (capex $1.05 Million plus investments $-24.38 Million) from operating cash flow of $39.83 Million. Explore Entrada Therapeutics Inc cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Entrada Therapeutics Inc (2023–2023)
Cash flow reinvestment rate of Entrada Therapeutics Inc from 2023 to 2023. Historical reinvestment intensity for Entrada Therapeutics Inc across 1 annual periods. Explore Entrada Therapeutics Inc capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
Entrada Therapeutics Inc Cash Flow Reinvestment Rate by Year (2023–2023)
Entrada Therapeutics Inc cash flow reinvestment rate by year from 2023 to 2023. Year-by-year capital reinvestment analysis for Entrada Therapeutics Inc. For the full cash flow conversion analysis, see TRDA cash generation efficiency.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2023 | 1.03x | $144.26 Million | $139.80 Million | $5.61 Million | — |